尿毒清颗粒联合非布司他片治疗高血压肾病合并高尿酸血症临床疗效研究  

Clinical of uremic clear granules combined with febuxostat tablets on treatment in hypertensive renal insufficiency with hyperuricemia

作　　者：刘远浩[1] LIU Yuanhao(Zhongshan People's Hospital,Zhongshan 528400,China)

机构地区：[1]中山市人民医院,广东中山528400

出　　处：《现代医院》2020年第3期427-430,434,共5页Modern Hospitals

摘　　要：目的探讨尿毒清颗粒联合非布司他片治疗高血压肾病合并高尿酸血症临床疗效。方法选取2017年1-9月诊治的高血压肾病合并高尿酸血症120例患者作为研究对象,根据随机数字法将患者分为尿毒清组、非布司他组和联合治疗组,所有患者均进行常规降压、低嘌呤饮食与高血压健康教育治疗,尿毒清组仅给予尿毒清治疗,非布司他组仅进行非布司他治疗,联合治疗组给予尿毒清联合非布司他治疗,每组40例,比较治疗前后患者尿素氮、血肌酐、血尿酸、血白蛋白、血清黄嘌呤氧化酶、腺苷脱氨酶、NO,收缩压、舒张压的变化,并观察药物的不良反应。结果三组治疗前尿素氮、血肌酐、血尿酸、血白蛋白、血清黄嘌呤氧化酶、腺苷脱氨酶、NO,收缩压、舒张压均无统计学意义(P>0.05)。治疗8周后三组血尿酸、尿素氮、血肌酐、血管性血友病因子、内皮素-1、黄嘌呤氧化酶、腺苷脱氨酶、卧位肾素、AngⅡ、收缩压、舒张压水平明显降低(P<0.05),尿酸达标率和NO水平均明显升高(P<0.05);联合治疗组上述指标均与尿毒清组和非布司他组存在明显差异(P<0.05);尿毒清组、非布司他组、联合治疗组不良反应总体发生率分别为13.41%、11.05%、12.81%,三组不良反应发生率无明显差异(P>0.05)。结论尿毒清颗粒联合非布司他片可明显改善肾功能、尿酸代谢、内皮功能和RAS活性,值得临床推广。Objective To investigate the clinical efficacy of Uremic Clear Granules combined with febuxostat in the treatment of hypertensive renal insufficiency complicated with hyperuricemia.Methods A total of 120 patients with hypertensive renal insufficiency with hyperuricemia in hospital were enrolled from January 2017 to September 2017.According to the random number method,the patients were divided into the uremic clearing group,the febuxostat group and the combined treatment group.All patients were treated with conventional antihypertensive,low-grade diet and high blood pressure health education.The uremic clearing treatment group was only with uremic clearing.The uremic clearing group was only treated with uremic clearing.The combination treatment group was treated with uremic clear combined with febuxostat.40 cases in each group,the changes of urea nitrogen,serum creatinine,blood uric acid,serum albumin,serum xanthine oxidase,adenosine deaminase,adenosine deaminase,NO,systolic blood pressure and diastolic blood pressure werecompared before and after treatment,and the adverse reactions of the drug was observed.Results There were no significant differences in the levels of urea nitrogen,serum creatinine,blood uric acid,serum albumin,serum xanthine oxidase,adenosine deaminase,adenosine deaminase,NO,systolic blood pressure and diastolic blood pressure before treatment(P>0.05).After 8 weeks of treatment,blood uric acid,urea nitrogen,serum creatinine,von Willebrand factor,endothelin-1,xanthine oxidase,adenosine deaminase,adenosine deaminase,renin,AngⅡ,systolic blood pressure and diastolic blood pressure levels in three groups were significantly lower(P<0.05),uric acid compliance rate and NO water level were significantly increased(P<0.05).The above indicators in the combination treatment group were significantly different from the uremic clearing group and the non-febuxostat group(P<0.05),and the incidence of adverse reactions in the uremic clearing treatment group was13.41%.The incidence of adverse reactions in the feb

关 键 词：尿毒清 非布司他 高血压肾病 高尿酸血症 

分 类 号：R544.1[医药卫生—心血管疾病]